Skip to content

The Finnish Diabetes Prevention Study

The Finnish Diabetes Prevention Study: A Follow-up Study on the Effect of a Dietary and Exercise Intervention in the Prevention of Diabetes and Its Vascular Complications

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00518167
Acronym
DPS
Enrollment
522
Registered
2007-08-20
Start date
1993-11-30
Completion date
2023-12-31
Last updated
2023-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes

Keywords

Type 2 diabetes, primary prevention, diet, physical activity, intervention, impaired glucose tolerance, lifestyle, randomized controlled study

Brief summary

The aim of this study is to clarify whether lifestyle intervention provided to people with high type 2 diabetes risk will lower the cumulative incidence of diabetes. Furthermore, the aim is to study the effect of lifestyle intervention on cardiovascular risk.

Interventions

BEHAVIORALIntensive lifestyle counselling

Individualized dietary and physical activity counselling aiming at 1. weight reduction 2. dietary fibre 15 g /1000 kcal or more 3. energy proportion of dietary fat less than 30% 4. energy proportion of saturated fat less than 10% 5. moderate physical activity \>30 minutes per day or 4 hours per week

Sponsors

University of Eastern Finland
CollaboratorOTHER
Finnish Diabetes Association
CollaboratorOTHER
University of Oulu
CollaboratorOTHER
Finnish Institute for Health and Welfare
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
40 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* impaired glucose tolerance (p-glucose 2 hours after a 75 g oral glucose load between 7.8 and 11.0 mmol/l) * body mass index 25 or higher

Exclusion criteria

* diabetes (previous gestational diabetes accepted) * other chronic disease rendering survival for 6 years * condition or medication affecting glucose tolerance * recent myocardial infarction

Design outcomes

Primary

MeasureTime frame
Diabetes incidenceDuring the intervention period + after the intervention has been stopped

Secondary

MeasureTime frame
CVD incidenceDuring the total follow up

Countries

Finland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 3, 2026